Dr. Mark Saunders is a consultant clinical oncologist with a primary focus on running clinical trials and evaluating novel agents with associated response/toxicity biomarkers and radiology in colorectal and anal cancer and pseudomyxoma. He is a member of several National Cancer Research Network (NCRN) CRC committees and collaborates with SchAAR to prepare material for NICE. Dr. Saunders obtained his medical degree from Charing Cross in 1986 and further trained at teaching hospitals in London. After five years in general medicine, he specialized in oncology, training at the Churchill Hospital in Oxford and later at The Christie in Manchester. As an Imperial Cancer Research Fund Fellow at the Churchill, he received an MRC grant to fund work that led to his PhD on gene therapy for tumor cell kill enhancement by bioreductive drugs, completed in 1999. Dr. Saunders received the Karol Sicher Research Fellowship, allowing him to work with Professor Ralph Weichselbaum at the University of Chicago. He became a consultant at The Christie in 1999 and chairs several Trial Management Groups (TMGs) and Data Monitoring Committees (DMCs). He is an advisor to the charity Beating Bowel Cancer and has expertise in chemotherapy, immunotherapy, radiotherapy, bowel cancer, colorectal cancer, gastro-intestinal cancers, and stomach cancer.